Search

Your search keyword '"TONINI G"' showing total 1,110 results

Search Constraints

Start Over You searched for: Author "TONINI G" Remove constraint Author: "TONINI G" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
1,110 results on '"TONINI G"'

Search Results

1. Short-Term Benefits of Smoking Cessation Improve Respiratory Function and Metabolism in Smokers

2. Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain

3. A Staphylococcus aureus Coinfection on a COVID-19 Pneumonia in a Breast Cancer Patient

4. Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study

5. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

6. Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial

8. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

10. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

12. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

13. Cascade of two-dimensional Fulde-Ferrell-Larkin-Ovchinnikov phases with anisotropy

15. Bone metastases in biliary cancers: A multicenter retrospective survey

16. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

17. Two tricritical lines from a Ginzburg-Landau expansion: application to the LOFF phase

18. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project.

20. 108P Safety results of post-neoadjuvant T-DM1 in the Italian compassionate use program (GIM26-TRASTHER study)

21. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX

23. Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial

26. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial

28. LBA22 Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study

29. 422P Nivolumab (NIV) plus FOLFOXIRI/bevacizumab (BEV) as first-line (1L) in metastatic colorectal cancer (mCRC) RAS/BRAF mutated (mut) patients, regardless of microsatellite status: Results of phase II NIVACOR Trial (GOIRC-03-2018)

30. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial

31. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

32. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

33. Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients

34. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

35. Understanding Factors Associated With Psychomotor Subtypes of Delirium in Older Inpatients With Dementia

36. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

37. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study

38. Correction to: Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study (Archives of Dermatological Research, (2022), 314, 6, (593-603), 10.1007/s00403-021-02243-w)

39. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

40. Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies

44. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX

45. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer

46. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

48. Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study

49. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

Catalog

Books, media, physical & digital resources